Dr. Adam P. Siegel, MD | Summit, WI ...

Dr. Adam P. Siegel

Claim this profile

Aurora Cancer Care-Milwaukee West

Studies Colorectal Cancer
Studies Colon Cancer
11 reported clinical trials
31 drugs studied

Area of expertise

1

Colorectal Cancer

Adam P. Siegel has run 3 trials for Colorectal Cancer. Some of their research focus areas include:

Stage IV
Stage III
dMMR negative
2

Colon Cancer

Adam P. Siegel has run 3 trials for Colon Cancer. Some of their research focus areas include:

Stage III
Stage IV
MLH1 positive

Affiliated Hospitals

Image of trial facility.

Aurora Cancer Care-Milwaukee West

Image of trial facility.

Aurora Cancer Care-Grafton

Clinical Trials Adam P. Siegel is currently running

Image of trial facility.

Relugolix + Radiation

for Advanced-Stage Prostate Cancer

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.

Recruiting

0 awards

Phase 2

Image of trial facility.

Apalutamide + Hormone and Radiation Therapies

for Prostate Cancer

This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

Recruiting

2 awards

Phase 3

More about Adam P. Siegel

Clinical Trial Related

6 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Adam P. Siegel has experience with

  • Nivolumab
  • Leucovorin Calcium
  • Fluorouracil
  • Ipilimumab
  • Avelumab
  • Irinotecan

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Adam P. Siegel specialize in?

Is Adam P. Siegel currently recruiting for clinical trials?

Are there any treatments that Adam P. Siegel has studied deeply?

What is the best way to schedule an appointment with Adam P. Siegel?

What is the office address of Adam P. Siegel?

Is there any support for travel costs?